CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Oramed Pharmaceuticals is developing an oral insulin delivery system using its POD™ technology, which protects insulin from degradation in the gastrointestinal tract. This innovation aims to improve adherence to diabetes treatment by providing a non-invasive alternative to injections.
Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe.
Caring for these individuals costs Europe €181M billion annually.
However, more needs to be done as T2DM and its related co-morbidities claim hundreds of thousands of lives each year in the region.
The early control of blood glucose levels (BGL) is the key to the prevention of the disease, and longer lifespans with better prognosis and higher quality of life for T2DM patients.
The last century has seen consi…
ORAMED LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
